ClinicalTrials.gg
TerminatedNCT04921358Updated Jun 29, 2025Results posted

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 3 interventional study of Tislelizumab and Docetaxel in Non-Small Cell Lung Cancer (NSCLC), sponsored by BeiGene. Terminated at 61 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 41
377 · median 39
Started
2021
with 4 others
Phase 3
9 of 41
none open now
Registered
10th of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared to docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who experienced disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody treatment, with the anti-PD-(L)1 antibody administered either in combination with or sequentially before or after the platinum-based chemotherapy.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or unresectable locally advanced or cytologically confirmed Non-Small Cell Lung Cancer (NCSLC), not amenable to treatment with curative intent
  2. Able to provide archival/fresh tumor tissues for biomarker analysis to assess expression and other biomarkers.
  3. No known Epidermal Growth Factor Receptor (EGFR) or B-Raf proto-oncogene (BRAF) sensitizing mutation, or anaplastic lymphoma kinase (ALK) rearrangement or ROS proto oncogene 1 (ROS1) rearrangement
  4. Radiographic progression per (RECIST) v1.1 on or after anti-PD-(L)1 containing therapy for locally advanced and unresectable or metastatic NSCLC.
  5. No prior anticancer therapy having the same mechanism of action as sitravatinib (eg, tyrosine kinase inhibitor with a similar target profile or vascular endothelial growth factor (VEGF)- or VEGFR inhibitor)
  6. At least 1 as defined based on RECIST v1.1 by investigator

Key Exclusion Criteria:

  1. Has received docetaxel as monotherapy or in combination with other therapies.
  2. Squamous NSCLC with central cavitation, or NSCLC with hemoptysis (> 50 mL/day)
  3. Participants with tumor shown by imaging to be located around important vascular structures or if the investigator determines that the tumor is likely to invade important blood vessels and may cause fatal bleeding.
  4. Active for metastatic NSCLC, or uncontrolled or untreated .
  5. Active diseases or history of autoimmune diseases that may relapse.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    Tislelizumab + Sitravatinib

    Participants received 200 mg of intravenous tislelizumab every 3 weeks, combined with 100 mg of oral sitravatinib daily until disease progression, intolerable toxicity, death, or withdrawal of consent, whichever occurred earlier.

    Drug: Tislelizumab · Drug: Sitravatinib

  • Active comparator
    Docetaxel

    Participants received 75 mg/m² of intravenous docetaxel once every 3 weeks until disease progression, intolerable toxicity, death, or withdrawal of consent, whichever occurred earlier.

    Drug: Docetaxel

Interventions

  • 200 mg intravenously once every 3 weeks

    Also known as: BGB-A317

  • 75 mg/m\^2 intravenously once every 3 weeks

  • 100 mg orally once daily

    Also known as: BGB-9468

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as the time from randomization until the date of death due to any cause. Kaplan-Meier methodology was used to estimate the median OS.

    Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

  2. Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

    Defined as the time from randomization until first documentation of disease progression as assessed by the IRC based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death from any cause, whichever occured first. Kaplan-Meier methodology was used to estimate the median PFS.

    Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

Secondary outcomes

  1. Progression Free Survival (PFS) as Assessed by the Investigator

    Defined as the time from randomization until first documentation of disease progression as determined by the investigator based on RECIST v1.1, or death from any cause, whichever occured first. Kaplan-Meier methodology was used to estimate the median PFS.

    Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

  2. Overall Response Rate (ORR)

    Defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the IRC per RECIST v1.1.

    Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

  3. Duration of Response (DOR)

    Defined as the time from the first occurrence of a documented objective response to the time of the first occurrence of disease progression, as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first.

    Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

  4. Disease Control Rate (DCR)

    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease per RECIST v1.1.

    Time frame: Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).

  5. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) and Physical Functioning Scores

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

    Time frame: Baseline and Cycle 5 Day 1 (Week 12) and Cycle 7 Day 1 (Week 18)

  6. Change From Baseline in EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scales

    The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.

    Time frame: Baseline and Cycle 5 Day 1 (Week 12) and Cycle 7 Day 1 (Week 18)

  7. Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS)

    The EQ-5D-5L comprises a descriptive module that includes five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a Visual Analogue Scale. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS records a participant's self-rated health on a vertical scale from 0 to 100, where 0 is 'the worst health you can imagine and 100 is 'the best health you can imagine'. A higher score indicates better health outcomes.

    Time frame: Baseline and Cycle 5 Day 1 (Week 12) and Cycle 7 Day 1 (Week 18)

  8. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: From the first dose through 30 days after the final dose or until new anticancer therapy, whichever came first, (a median treatment duration of approximately 4 months in Arm 1 and 2 months in Arm 2).

07

Results

Posted Jun 29, 2025

Participant flow

Participants were enrolled across multiple study centers in China and Australia. The first participant was dosed on July 27th, 2021, and the last participant completed the study on December 20th, 2023. A decision to terminate the study was made on September 25th, 2023.

Participant flow — Overall Study
MilestoneTislelizumab + SitravatinibDocetaxel
Started187190
Treated186177
Completed00
Not completed187190
Withdrew: Withdrawal by subject613
Withdrew: Lost to follow-up36
Withdrew: Study terminated by sponsor8689
Withdrew: Death9282

Outcome measures

PrimaryOverall Survival (OS)

Defined as the time from randomization until the date of death due to any cause. Kaplan-Meier methodology was used to estimate the median OS.

Time frame:
Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
Reported as:
Median · Months
Overall Survival (OS)
MonthsTislelizumab + SitravatinibDocetaxel
Overall Survival (OS)11.5 (9.4 to 14.6)11.4 (9.9 to 15.0)
Statistical analysis
  • Tislelizumab + Sitravatinib vs Docetaxel · Hazard ratio (hr): 1.02 · 95% CI 0.75 to 1.39Hazard ratio and 95% confidence intervals (CIs) were estimated using a Cox regression model stratified by histological subtype (nonsquamous vs squamous), race (Asian vs Non-Asian) and PD-L1 expression (\<1% Tumor Cells (TC) vs \>=1% TC).
PrimaryProgression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

Defined as the time from randomization until first documentation of disease progression as assessed by the IRC based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death from any cause, whichever occured first. Kaplan-Meier methodology was used to estimate the median PFS.

Time frame:
Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
Reported as:
Median · Months
Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
MonthsTislelizumab + SitravatinibDocetaxel
Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)4.4 (4.0 to 5.7)2.9 (2.6 to 4.2)
Statistical analysis
  • Tislelizumab + Sitravatinib vs Docetaxel · Hazard ratio (hr): 0.82 · 95% CI 0.62 to 1.07Hazard ratio and 95% CIs were estimated using a Cox regression model stratified by histological subtype (nonsquamous vs squamous), race (Asian vs Non-Asian) and PD-L1 expression (\<1% TC vs \>=1% TC).
SecondaryProgression Free Survival (PFS) as Assessed by the Investigator

Defined as the time from randomization until first documentation of disease progression as determined by the investigator based on RECIST v1.1, or death from any cause, whichever occured first. Kaplan-Meier methodology was used to estimate the median PFS.

Time frame:
Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
Reported as:
Median · Months
Progression Free Survival (PFS) as Assessed by the Investigator
MonthsTislelizumab + SitravatinibDocetaxel
Progression Free Survival (PFS) as Assessed by the Investigator4.4 (4.0 to 5.6)2.9 (2.6 to 4.1)
Statistical analysis
  • Tislelizumab + Sitravatinib vs Docetaxel · Hazard ratio (hr): 0.64 · 95% CI 0.50 to 0.83Hazard ratio and 95% CIs were estimated using a Cox regression model stratified by histological subtype (nonsquamous vs squamous), race (Asian vs Non-Asian) and PD-L1 expression (\<1% TC vs \>=1% TC).
SecondaryOverall Response Rate (ORR)

Defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the IRC per RECIST v1.1.

Time frame:
Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsTislelizumab + SitravatinibDocetaxel
Overall Response Rate (ORR)12.3 (8.0 to 17.9)12.6 (8.3 to 18.2)
SecondaryDuration of Response (DOR)

Defined as the time from the first occurrence of a documented objective response to the time of the first occurrence of disease progression, as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first.

Time frame:
Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
Reported as:
Median · months
Duration of Response (DOR)
monthsTislelizumab + SitravatinibDocetaxel
Duration of Response (DOR)6.0 (3.2 to 8.5)NA (5.4 to NA)
SecondaryDisease Control Rate (DCR)

Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease per RECIST v1.1.

Time frame:
Until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive (a median follow-up of approximately 8 months).
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsTislelizumab + SitravatinibDocetaxel
Disease Control Rate (DCR)69.5 (62.4 to 76.0)53.7 (46.3 to 60.9)
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) and Physical Functioning Scores

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

Time frame:
Baseline and Cycle 5 Day 1 (Week 12) and Cycle 7 Day 1 (Week 18)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) and Physical Functioning Scores
score on a scaleTislelizumab + SitravatinibDocetaxel
Global Health Status at Cycle 5-5.5 ± 16.05-3.0 ± 18.69
Global Health Status at Cycle 7-6.1 ± 15.86-3.4 ± 17.25
Physical Functioning at Cycle 5-4.1 ± 12.76-5.1 ± 15.89
Physical Functioning at Cycle 7-2.8 ± 12.30-3.1 ± 16.98
SecondaryChange From Baseline in EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scales

The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.

Time frame:
Baseline and Cycle 5 Day 1 (Week 12) and Cycle 7 Day 1 (Week 18)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scales
score on a scaleTislelizumab + SitravatinibDocetaxel
Coughing at Cycle 51.6 ± 30.09-2.4 ± 27.61
Coughing at Cycle 7-5.2 ± 25.08-1.3 ± 29.49
Dyspnoea at Cycle 52.6 ± 19.094.5 ± 16.76
Dyspnoea at Cycle 7-0.9 ± 14.662.1 ± 14.43
Chest Pain at Cycle 5-0.6 ± 24.45-0.5 ± 20.21
Chest Pain at Cycle 7-2.4 ± 22.43-1.3 ± 16.12
SecondaryChange From Baseline in European Quality of Life-5 Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS)

The EQ-5D-5L comprises a descriptive module that includes five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a Visual Analogue Scale. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS records a participant's self-rated health on a vertical scale from 0 to 100, where 0 is 'the worst health you can imagine and 100 is 'the best health you can imagine'. A higher score indicates better health outcomes.

Time frame:
Baseline and Cycle 5 Day 1 (Week 12) and Cycle 7 Day 1 (Week 18)
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS)
score on a scaleTislelizumab + SitravatinibDocetaxel
Cycle 5-6.1 ± 14.27-3.5 ± 13.76
Cycle 7-5.9 ± 12.31-3.2 ± 12.60
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

Time frame:
From the first dose through 30 days after the final dose or until new anticancer therapy, whichever came first, (a median treatment duration of approximately 4 months in Arm 1 and 2 months in Arm 2).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsTislelizumab + SitravatinibDocetaxel
TEAEs183162
SAEs8366

Adverse events

Collected over All-cause mortality is reported from randomization until the study completion data cut-off date of December 20, 2023, or the last available date confirming participants were alive ( a median follow-up of approximately 8 months). Adverse events are reported from the first dose through 30 days after the final dose or until new anticancer therapy, whichever came first, (a median treatment duration of approximately 4 months in Arm 1 and 2 months in Arm 2).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab + Sitravatinib92/187 (49.2%)83/186 (44.6%)181/186 (97.3%)
Docetaxel82/190 (43.2%)66/177 (37.3%)150/177 (84.7%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventTislelizumab + SitravatinibDocetaxel
PneumoniaInfections and infestations16/18617/177
NeutropeniaBlood and lymphatic system disorders0/1868/177
Neutrophil count decreasedInvestigations0/1868/177
White blood cell count decreasedInvestigations0/1868/177
Febrile neutropeniaBlood and lymphatic system disorders0/1867/177
Pleural effusionRespiratory, thoracic and mediastinal disorders1/1866/177
DeathGeneral disorders6/1861/177
HaemoptysisRespiratory, thoracic and mediastinal disorders5/1861/177
General physical health deteriorationGeneral disorders4/1862/177
Immune-mediated hepatitisHepatobiliary disorders4/1860/177
Most frequent other events
Showing 10 of 89
Most frequent other events
EventTislelizumab + SitravatinibDocetaxel
Aspartate aminotransferase increasedInvestigations111/18617/177
Alanine aminotransferase increasedInvestigations96/18615/177
AnaemiaBlood and lymphatic system disorders61/18684/177
DiarrhoeaGastrointestinal disorders82/18624/177
Blood creatine phosphokinase MB increasedInvestigations74/1863/177
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders67/1860/177
White blood cell count decreasedInvestigations11/18662/177
AlopeciaSkin and subcutaneous tissue disorders5/18659/177
HypoalbuminaemiaMetabolism and nutrition disorders57/18641/177
Neutrophil count decreasedInvestigations10/18654/177

Baseline characteristics

The Intent-to-Treat (ITT) analysis set consists of all participants who were randomized to a treatment arm.

Age, Continuous
Age, Continuous(Years)Tislelizumab + SitravatinibDocetaxelTotal
Mean61.2 ± 8.4361.3 ± 8.7761.3 ± 8.60
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab + SitravatinibDocetaxelTotal
Female343973
Male153151304
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab + SitravatinibDocetaxelTotal
Asian175177352
White121325
Region of Enrollment
Region of Enrollment(participants)Tislelizumab + SitravatinibDocetaxelTotal
China174175349
Australia131528
Histology
Histology(Participants)Tislelizumab + SitravatinibDocetaxelTotal
Squamous9697193
Non-squamous9193184
PD-L1 Expression Status
PD-L1 Expression Status(Participants)Tislelizumab + SitravatinibDocetaxelTotal
>= 1% Tumor Cells7171142
< 1% Tumor Cells116119235
08

Study locations

61 sites
  • Blacktown Cancer and Haematology Centre
    Blacktown, New South Wales 2148, Australia
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • The Tweed Valley Hospital
    Cudgen, New South Wales 2487, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
  • Cancer Research South Australia
    Adelaide, South Australia 5000, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Sunshine Hospital
    St Albans, Victoria 3021, Australia
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
    Hefei, Anhui 230088, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
  • Xinqiao Hospital Affiliated to the Army Medical University
    Chongqing, Chongqing Municipality 400037, China
  • Daping Hospital, Third Military Medical University
    Chongqing, Chongqing Municipality 400042, China
  • Fujian Provincial Hospital
    Fuzhou, Fujian 350001, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • Cancer Hospital Chinse Academy of Medical Sciences, Shenzhen Center
    Shenzhen, Guangdong 518116, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The First Peoples Hospital of Chenzhou
    Chenzhou, Hunan 423000, China
  • The Second Hospital, University of South China
    Hengyang, Hunan 430407, China
  • Changzhou No Peoples Hospital, the Affiliated Hospital of Nanjing Medical University Branch Cheng
    Changzhou, Jiangsu 213003, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210009, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • The Affiliated Hospital of Qingdao University Branch Laoshan
    Qingdao, Shandong 266000, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Sichuan Cancer Hospital and Institute
    Chengdu, Sichuan 610041, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830000, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Taizhou Hospital of Zhejiang
    Taizhou, Zhejiang 317000, China
09

References and documents

Publications

  • Zhou Q, Zhao J, Gao B, et al. SAFFRON-301: A Phase 3 Study of Tislelizumab With Sitravatinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy and an Anti-PD-1/PD-L1 Antibody. Poster presented at: ESMO Congress 2022; September, 2022; Paris, France.
  • Zhou Q, Gao B, et al. SAFFRON-301: Sitravatinib PLUS Tislelizumab in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2023, 28 months.

Results were first posted in Jun 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
Jun 10, 2021
StartActual
Jul 27, 2021
Primary completionActual
Dec 20, 2023
CompletionActual
Dec 20, 2023
Results first posted
Jun 29, 2025
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04921358
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jun 10, 2021
Start date
Jul 27, 2021
Primary completion
Dec 20, 2023
Completion
Dec 20, 2023
Results posted
Jun 29, 2025
Last update
Jun 29, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Sitravatinib

Start the discussion